StemCells Inc., of Newark, Calif., said the California Institute of Regenerative Medicine approved the firm's application of a planning grant of $100.000, which will help fund the development of human neural stem cell product HuCNS-SC cells in Alzheimer's disease by enabling StemCells and its collaborators at the University of California, Irvine, to prepare and submit for a Disease Team Therapy Development Research Award, which could bring the firm up to $20 million over four years to support
NovaHep focuses on liver stem cells, while Recopharma focuses on recombinant glyco proteins...Although Allenex has been the sole financier of both companies to date, it said funding such developmental work is challenging in the current environment, and it needs to prioritize its own organ and stem cell transplantation business
BioWorld International | Wednesday, August 31, 2011
Inc., of San Jose, Calif., to make its stromal vascular fraction-containing adipose-derived adult stem cells available for veterinary use...Adipose stem cells are being investigated for aesthetics, arthritis, orthopedic injuries, wound healing, congestive heart failure, gum regeneration and other diseases
NovaHep focuses on liver stem cells, while Recopharma focuses on recombinant glyco proteins...Although Allenex has been the sole financier of both companies to date, it said funding such developmental work is challenging in the current environment, and it needs to prioritize its own organ and stem cell transplantation business
BioTime Inc., of Alameda, Calif., said four of its human embryonic stem cell lines will be included in the National Institutes of Health Human Embryonic Stem Cell Registry and can be used for federally funded research
Neuralstem Inc., of Rockville, Md., received a $1.6 million contract from the Department of Defense (DOD) to develop a stem cell treatment for brain cancer, with a goal of submitting a product to the FDA by 2015
to use BioWa's Potelligent antibody targeting technology in combination with ArGen-X's SIMPLE antibody discovery platform...Gruppo Angelini SpA, of Rome, and Labopharm Inc., of Laval, Quebec, agreed to restructure their joint venture partnership for Oleptro, terminating existing agreements, with Labopharm granting Angelini an exclusive license and rights to the depression drug in the U.S., Canada and other countries in exchange for a royalty on product sales...The facility is expected to be online in
BioWorld International | Wednesday, August 3, 2011
Marshall Edwards Inc., of San Diego, reported results of a preclinical study that showed NV-128 can target the mitochondria in patient-derived ovarian cancer stem cells to induce cell death in an otherwise chemo-resistant cell population
The 15-patient trial is a result of research initiated in 2002 by researchers at Genethon who developed an ex vivo approach that uses an HIV-derived lentiviral vector to transfer genes into autologous CD34+ hematopoietic stem cells from WAS patients
Ltd., of South Korea, designed to enhance the efforts of the two companies' international joint venture, Stem Cell & Regenerative Medicine International (SCRMI...The 15-patient trial is a result of research initiated in 2002 by researchers at Genethon who developed an ex vivo approach that uses an HIV-derived lentiviral vector to transfer genes into autologous CD34+ hematopoietic stem cells from WAS patients
International Stem Cell Corp., of Carlsbad, Calif., started a series of animal studies to test the safety of neuronal cells derived from its human parthenogenetic stem cells, as well as the cells' ability to develop into functioning dopaminergic neuron-like cells
The company previously was granted orphan drug status for NurOwn, a process involving the use of adult human mesenchymal stem cells derived from patients' bone marrow
BioTime Inc., of Alameda, Calif., received a 10-month $335,900 Small Business Innovation Research grant from the National Institutes of Health to develop HyStem microcarriers for the propagation of human stem cells and as a means of cell delivery for human clinical applications
Celprogen, of Los Angeles, has developed neuronal stem cells that can be differentiated into neurons as an alternative for cell-based therapy for neurological diseases including Alzheimer's...Patient dosing has begun in Chimerix Inc.'s AdV HALT Trial, a Phase II study evaluating the safety and efficacy of preemptive treatment with CMX001 to prevent adenovirus disease following hematopoietic stem cell transplantation
Stem Cell Therapeutics Corp., of Calgary, Alberta, presented preclinical data showing that its NTx-428 regimen, comprising treatment with human chorionic gonadotropin followed by erythropoietin, significantly decreased brain matter loss and improved functional recovery of symptoms in a rodent model of fluid percussion injury
StemCells Inc., of Newark, Calif., said the California Institute of Regenerative Medicine approved the firm's application of a planning grant of $100.000, which will help fund the development of human neural stem cell product HuCNS-SC cells in Alzheimer's disease by enabling StemCells and its collaborators at the University of California, Irvine, to prepare and submit for a Disease Team Therapy Development Research Award, which could bring the firm up to $20 million over four years to support